蒽环类耐药三阴型乳腺癌二线化疗用药方案分析  

Analysis of Second-line Chemotherapy Regimens for Anthracycline Resistant Triple Negative Breast Cancer

作　　者：颜昕 杨乐艺 张晓玲 郭毓娟 罗立雄 YAN Xin;YANG Leyi;ZHANG Xiaoling;GUO Yujuan;LUO Lixiong(The Third Department of General Surgery,Zhangzhou Affiliated Hospital of Fujian Medical University,Zhangzhou Fujian 363000,China;Department of Pharmacy,Zhangzhou Affiliated Hospital of Fujian Medical University,Zhangzhou Fujian 363000,China)

机构地区：[1]福建医科大学附属漳州市医院普外三科,福建漳州363000 [2]福建医科大学附属漳州市医院药剂科,福建漳州363000

出　　处：《中国卫生标准管理》2018年第14期77-80,共4页China Health Standard Management

摘　　要：目的探讨蒽环类耐药三阴型乳腺癌患者的联合二线化疗用药方案。方法选取2013年2月—2017年3月我院蒽环类耐药三阴型乳腺癌患者100例作为研究对象。根据化疗方案的不同,将其分为研究组和对照组。研究组接受长春瑞滨联合多西他赛化疗,对照组接受长春瑞滨联合卡培他滨治疗。对比两组患者的治疗疗效;两组中位生存期;两组不良反应。结果研究组和对照组治疗蒽环类耐药三阴型乳腺癌的治疗有效率分别为56%、30%,差异有统计学意义(P<0.05);研究组和对照组中位生存期分别为(6.32±0.74)个月、(4.36±0.51)个月,差异具有统计学意义(P<0.05);两组不良反应发生率对比,差异具有统计学意义(P<0.05)。结论长春瑞滨联合多西他赛治疗蒽环类耐药三阴性乳腺癌的疗效优于长春瑞滨联合卡培他滨化疗方案,安全性好。Objective To explore the regimen of combined second-line chemotherapy for anthracycline resistant triple negative breast cancer.Methods 100 patients with anthracycline resistant triple negative type breast cancer from February 2013 to March 2017 were selected as the study objects.According to the difference of chemotherapy regimen,they were divided into study group and control group.The study group received chemotherapy combined with vinorelbine and docetaxel.The control group was treated with vinorelbin combined with capecitabine.The therapeutic effects of the two groups were compared,the median survival time of the two groups,and the adverse reactions of the two groups was compared.Results The therapeutic effect of the study group and the control group on anthracycline resistant triple negative type breast cancer was 56%and 30%respectively,and the difference was statistically significant(P<0.05).The median survival time of the study group and the control group were(6.32±0.74)months and(4.36±0.51)months respectively,and the difference was statistically significant(P<0.05).The incidence of adverse reactions between the two groups was statistically significant(P<0.05).Conclusion The effect of vinorelbine combined with docetaxel in the treatment of anthracycline resistant triple negative breast cancer is better than that of vinorelbine combined with capecitabine chemotherapy.

关 键 词：蒽环类 耐药 乳腺癌 二线化疗 

分 类 号：R737[医药卫生—肿瘤]